Equities

Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

Actions
  • Price (EUR)2.72
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-83.89%
  • Beta--
Data delayed at least 15 minutes, as of Aug 29 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Sonoma Pharmaceuticals Inc had revenues fall -4.05% from 13.27m to 12.74m, though the company grew net income from a loss of 5.15m to a smaller loss of 4.84m.
Gross margin38.17%
Net profit margin-35.91%
Operating margin-36.49%
Return on assets-30.85%
Return on equity-74.65%
Return on investment-41.88%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Sonoma Pharmaceuticals Inc fell by 692.00k. Cash Flow from Financing totalled 1.68m or 13.16% of revenues. In addition the company used 2.40m for operations while cash used for investing totalled 2.00k.
Cash flow per share-7.25
Price/Cash flow per share--
Book value per share5.24
Tangible book value per share5.24
More ▼

Balance sheet in USDView more

Sonoma Pharmaceuticals Inc uses little debt in its capital structure as supported by a debt to capital ratio of 3.94%.
Current ratio3.18
Quick ratio2.47
Total debt/total equity0.041
Total debt/total capital0.0394
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.